Subacute Cutaneous Lupus Erythematosus Induced or Exacerbated by Terbinafine
Open Access
- 1 September 2001
- journal article
- observation
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 137 (9) , 1196-1198
- https://doi.org/10.1001/archderm.137.9.1196
Abstract
Background Subacute cutaneous lupus erythematosus is a nonscarring, non–atrophy-producing photosensitive cutaneous disorder. Half of the patients have 4 or more of the criteria for classification as systemic lupus erythematosus. In some patients, drugs induce or exacerbate the cutaneous disease. Observation We describe 5 patients who had either an exacerbation or a new onset of subacute cutaneous lupus erythematosus while taking terbinafine for presumed onychomycosis. Conclusion In general, terbinafine is a safe drug, but perhaps patients with known lupus erythematosus or photosensitivity are predisposed to drug-induced or drug-exacerbated disease.Keywords
This publication has 5 references indexed in Scilit:
- Clinical assessment of drug-induced diseaseThe Lancet, 2000
- Terbinafine-induced subacute cutaneous lupus erythematosusBritish Journal of Dermatology, 1998
- Terbinafine-induced lupus erythematosusBritish Journal of Dermatology, 1998
- Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapyPublished by Elsevier ,1997
- Subacute Cutaneous Lupus Erythematosus Associated with Hydrochlorothiazide TherapyAnnals of Internal Medicine, 1985